Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Trevor J. Powles"'
Immunohistochemical analysis of biomarkers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::801afa6bdff66b0c546ca41b160ade61
https://doi.org/10.1158/1940-6207.22532561
https://doi.org/10.1158/1940-6207.22532561
Autor:
Simone I, Detre, Susan, Ashley, Kabir, Mohammed, Ian E, Smith, Trevor J, Powles, Mitch, Dowsett
Publikováno v:
Cancer prevention research (Philadelphia, Pa.). 10(3)
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1fe13cb0f47a55f51f676ff94e5b8fcf
https://pubmed.ncbi.nlm.nih.gov/28100469
https://pubmed.ncbi.nlm.nih.gov/28100469
Autor:
Caroline Reuter, Adam R. Brentnall, Jack Cuzick, Ivana Sestak, Corrinne V. Segal, Mitchell Dowsett, Anthony Howell, William G. Newman, Trevor J. Powles, Helen Byers, Simone Detre
Publikováno v:
Brentnall, A R, Cuzick, J, Byers, H, Segal, C, Reuter, C, Detre, S, Sestak, I, Howell, A, Powles, T J, Newman, W G & Dowsett, M 2016, ' Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials ', Breast Cancer Research and Treatment, vol. 158, no. 3, pp. 591-596 . https://doi.org/10.1007/s10549-016-3885-x
A case–control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a246923f3a8472dd4611a16a5a0ee1f
https://europepmc.org/articles/PMC4977422/
https://europepmc.org/articles/PMC4977422/
Publikováno v:
Journal of Clinical Oncology. 35:2719-2720
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcc95aa2d5a5c05c073c04dae320a2e9
https://doi.org/10.1200/jco.2017.73.6157
https://doi.org/10.1200/jco.2017.73.6157
Publikováno v:
JAMA Oncology. 4:1477
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b784933c29b0c64da7596eb0647fd15
https://doi.org/10.1001/jamaoncol.2018.2674
https://doi.org/10.1001/jamaoncol.2018.2674
Autor:
D. Gareth Evans, Jenny Affen, Lesley Ann Flook, Eugene V. McCloskey, Sue Ashley, Anthony Howell, Trevor J. Powles, Rosemary Greenhalgh, A. Tidy
Publikováno v:
Powles, T J, Howell, A, Evans, D G, McCloskey, E V, Ashley, S, Greenhalgh, R, Affen, J, Flook, L A & Tidy, A 2008, ' Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer ', Menopause International, vol. 14, no. 1, pp. 6-12 . https://doi.org/10.1258/mi.2007.007033
Objective To assess the safety and tolerability of a standardized 40 mg red clover isoflavone dietary supplement (Promensil®, Novogen) in women with a family history of breast cancer to evaluate the feasibility of using the supplement for prevention
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985d69d0f57282174bacabee21a85677
https://doi.org/10.1258/mi.2007.007033
https://doi.org/10.1258/mi.2007.007033
Autor:
Steven D. Heys, Robert E. Coleman, Richard Eastell, David M. Reid, Peter Selby, Anthony Howell, Trevor J. Powles, Julie Doughty, Eugene V. McCloskey
Publikováno v:
Cancer Treatment Reviews. 34:S3-S18
In postmenopausal women, the use of aromatase inhibitors increases bone turnover and induces bone loss at sites rich in trabecular bone at an average rate of 1-3% per year leading to an increase in fracture incidence compared to that seen during tamo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f28eefd01fc2c7600a1b8916f2fb74
https://doi.org/10.1016/j.ctrv.2008.03.007
https://doi.org/10.1016/j.ctrv.2008.03.007
Publikováno v:
JNCI Journal of the National Cancer Institute. 99:283-290
Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial Background Several clinical trials have reported an early reduction in breast cancer incidence in healthy women using tamoxifen to reduce t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e1df368cbe622ff3d27e5c20dac9d8
https://doi.org/10.1093/jnci/djk050
https://doi.org/10.1093/jnci/djk050
Autor:
Trevor J. Powles
Publikováno v:
Annals of the New York Academy of Sciences. 949:109-112
The Royal Marsden Hospital (RMH) trial - Key points and remaining questions. The reported interim analysis of the Royal Marsden chemoprevention trial, giving tamoxifen (20 mg/day) for up to 8 years to healthy women at increased risk of breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4128fb7ac5c291ceef96f2e001d8017c
https://doi.org/10.1111/j.1749-6632.2001.tb04008.x
https://doi.org/10.1111/j.1749-6632.2001.tb04008.x
Autor:
Trevor J. Powles
Publikováno v:
European Journal of Cancer. 39:572-579
Clinical trials of the selective oestrogen receptor modulator (SERM), tamoxifen, have shown an early reduction in risk of breast cancer in healthy women of approximately 40%, but with associated risks and benefits to normal tissues. An overall clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4def5b03229a458a0079863091ccad
https://doi.org/10.1016/s0959-8049(02)00771-2
https://doi.org/10.1016/s0959-8049(02)00771-2